Wegovy sustains weight loss for at least 4 years
WIRED — May 16, 2024, 12:00 PM UTC
Summary: A study on Wegovy (semaglutide) showed sustained weight loss over four years in 17,604 participants without diabetes. The drug led to an average weight loss of 10.2% compared to a placebo group's 1.5%, with a treatment difference of 8.7%. The SELECT trial found that 52.4% of those on semaglutide moved to a lower BMI category. Researchers suggest broad use of semaglutide for overweight individuals with cardiovascular disease.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.